Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2007-05-08
2007-05-08
Kwon, Brian (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S603000
Reexamination Certificate
active
10056528
ABSTRACT:
The present invention relates to methods and compositions for treating selected conditions of the central and peripheral nervous systems employing non-synaptic mechanisms. More specifically, one aspect of the present invention relates to methods and materials for treating seizure and seizure disorders, epilepsy, status epilepticus, migraine, spreading depression, intracranial hypertension; for treating the pathophysiological effects of head trauma, stroke, ischemia and hypoxia; for treating or protecting from the pathophysiological effects of neurotoxic agents such as ethanol; and for treating neurophsyciatric disorders and central nervous system edema by administering agents that modulate ionic concentrations and/or ionic gradients in the brain, particularly ion-dependent or cation-chloride cotransporter antagonists. Electrolyte cotransport antagonists and combinations of such compositions with other agents for treating various conditions are disclosed. The present invention also relates to methods and compositions for treating pain by administering ion-dependent cotransporter antagonists. Methods and compositions for enhancing cortical function, for example, in centers of cognition, learning and memory, by administering ion-dependent cotransporter agonists are disclosed.
REFERENCES:
patent: 5256687 (1993-10-01), Becker et al.
patent: 5475008 (1995-12-01), Carling et al.
patent: 5753651 (1998-05-01), dePadova
patent: 6040331 (2000-03-01), Yamamoto et al.
patent: 6130234 (2000-10-01), Bigge et al.
patent: 6369094 (2002-04-01), Bentley et al.
patent: 6432986 (2002-08-01), Levin
patent: 6669951 (2003-12-01), Rothbard et al.
“Treatment of a Prolonged Migrainous Aura with Intravenous Furosemide”, Rosen, T.D., Sep. 2000, Neurology:55, 732-733.
“Acetazolamide Testing of Cerebral Vasodilator Capacity Provokes “Vascular” But Not Tension Headaches”, Shirai et al., abstract, The Journal of Head and Face Pain, vol. 36, Issue. 10 p. 589, Nov. 1996.
Strategies For Optimizing Migraine Management, Proceedings From A CME Teleconference Series, Sep. 10-14, 2001, pp. 1-26, especially p. 8, para. 5).
“The Migraineur's Guide to Migraine, http://www.headachecare.com”, 2000.
“Topiramate Inhibits Cortical Spreading Depression in Rat and Cat: Impact in Migraine Aura”, Akerman et al., abstract, Neuroreport, Aug. 22, 2005, 16(12):1383-7.
“Primay Structure and Functional Expression of a cDNA Encoding the Thiazide-Sensitive, Electroneutral Sodium-Chloride Cotransporter”, Gamba et al., Proc. Natl. Acad, Sci, USA, vol. 90, pp. 2749-2753, Apr. 1993.
“Cortical Spreading Depression Reduces Dural Blood Flow—a Possible Mechanism for Migraine Pain”, Lambert et al., abstract, Cephalalgia, Dec. 1994, 14(6):430-6; discussion 393-4.
Read, S.J., et al., “Furosemide inhibits regenerative cortical spreading depression in anaesthetized cats”,Cephalalgia, vol. 17, pp. 826-832 (1997).
Mathew, Ninan T., et al., “Coexistence of migraine and idiopathic intracranial hypertension without papilledema”,Neurologyl, vol. 46, pp. 1226-1230 (May 1996).
Welch, K.M.A., M.D., “Pathogenesis of Migraine”,Seminars in Neurology, vol. 17, No. 4, pp. 335-341 (1997).
Parsons, Andrew W., “Recent advances in mechanisms of spreading depression,”Current Opinion in Neurology, vol. 11, pp. 227-231 (1998).
Snow, Robert W., et al., “Electrophysiological and Optical Changes in Slices of Rat Hippocampus During Spreading Depression,”Journal of Neurophysiology, vol. 50, No. 3, pp. 561-572 (Sep. 1983).
Walz, Wolfgang et al., “Intense Furosemide-Sensitive Potassium Accumulation in Astrocytes in the Presence of Pathologically High Extracellular Potassium Levels,”Journal of Cerebral Blood Flow and Metabolism, vol. 4, pp. 301-304 (1984).
Kimelberg, H.K. et al., “Furosemide- and bumetanide-sensitive ion transport and volume control in primary astrocyte cultures from rat brain,”ABSTRACT—Brain Res., vol. 361, Nos. 1-2, pp. 125-134 (Dec. 30, 1985).
Kimelberg, H.K., “Anisotonic media and glutamate-induced ion transport and volume responses in primary astrocyte cultures,”ABSTRACT—J. Physiol. (Paris), vol. 82, Nos. 4, pp. 294-303 (1987).
Kempski, O. et al., “Glial ion transport and volume control,”ABSTRACT—Ann N.Y. Acad. Sci., vol. 633, pp. 306-317 (1991).
Walz, W., “Role of Na/K/Cl cotransport in astrocytes,”ABSTRACT—Can. J. Physiol. Pharmacol., vol. 70, Suppl., pp. S260-S262 (1992).
Walz, W., “Role of astrocytes in the spreading depression signal between ischemic core and penumbra,”ABSTRACT—Neurosci. Biobehav. Rev., vol. 21, No. 2., pp. 135-142 (1997).
Hochman, Daryl W., et al., “Extracellular Chloride and the Maintenance of Epileptiform Activity in Hippocampal Slices,”ABSTRACT—Society for Neuroscience, vol. 23, Part 2., p. 2425 (1997).
Sinha, S.R., et al., “Effects of Furosemide on Normal and Epileptiform Evoked Activity in Area CA1 of Guinea Pig Hippocampal Slice,”ABSTRACT—Society for Neuroscience, vol. 23, Part 2., p. 2425 (1997).
Collins, Michael A., et al., “Brian damage due to episodic alcohol exposure in vivo and in vitro: furosemide neuroprotection implicates edema-based mechanism,”The FASEB Journal, vol. 12, pp. 221-230 (Feb. 1998).
Hochman, Daryl W., et al., “Dissociation of Synchronization and Excitability of Furosemide Blockade of Epileptiform Activity,”Science, vol. 270, pp. 99-102 (Oct. 6, 1995).
Pinegin, L.E., et al., “Effect of furosemide on intracranial pressure in patients with intracranial hypertension,”ABSTRACT—Medline(1983).
Misiuk, N.S., et al., “Effect of glycerol, mannitol and lasix on cerebrospinal fluid pressure in the acute period of a stroke,”ABSTRACT—Medline(1981).
NeuroTherapeutics Pharma LLC
Sleath Janet
Speckman Ann W.
Speckman Law Group PLLC
LandOfFree
Method of treating migraine headache without aura does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating migraine headache without aura, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating migraine headache without aura will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3736792